Local Retention and Combination Effects of Biocompatible
Doxorubicin-Loaded and Radioiodine-Labeled Microhydrogels in Cancer
Therapy
- Publication date
- Publisher
Abstract
I-131-labeled chitosan microhydrogels
(I-131-CMH) that are retained
at an injection site without leaking free I-131 into normal tissue
can provide opportunities to improve cancer therapy. This study focuses
on the development of doxorubicin-loaded I-131-CMH (Dox-I-131-CMH)
for use in radiochemotherapy against cancer. The radiolabeling of
I-131-CMH was found to be stable over a period of 2 weeks with no
disassociation of free I-131, and Dox showed a sustained release from
the CMH. When I-131-CMH were injected into the thigh muscle or tumor
tissue, in vivo gamma imaging showed a retention at the injection
site with no significant leakage of I-131 into other areas of normal
tissue, and after an intrahepatic arterial injection, I-131-CMH were
selectively retained in the liver. Dox-I-131-CMH had significant synergistic
therapeutic effects of radiation and chemotherapy on mouse breast
cancer models. In this regard, Dox-I-131-CMH may be a new alternative
agent for cancer therapy